Cadus Corporation is a U.S. company best known for its earlier work in biopharmaceutical research. In the 1990s–2000s it developed cell-based assay and yeast genetics platforms to identify and screen drug candidates, particularly for G protein–coupled receptor (GPCR) targets, and conducted discovery collaborations with major pharmaceutical firms.
After divesting its drug discovery assets, Cadus shifted to residential real estate activities in South Florida, acquiring, redeveloping, and constructing single-family properties. In subsequent years, the company undertook an orderly wind-down and liquidation of remaining assets. Cadus has been associated with investment vehicles affiliated with Carl C. Icahn.
Brett Icahn joins IFF's Audit and Transaction Committees, while Richard Mulligan joins the Innovation Committee, following a cooperation agreement with Icahn Capital.
